Cation/proton antiporters: novel structure-driven pharmaceutical opportunities

Gal Masrati; Amit Kessel; Nir Ben-Tal

doi:10.1016/j.tips.2023.02.006

Cation/proton antiporters: novel structure-driven pharmaceutical opportunities

Trends Pharmacol Sci. 2023 May;44(5):258-262. doi: 10.1016/j.tips.2023.02.006. Epub 2023 Mar 16.

Authors

Gal Masrati¹, Amit Kessel¹, Nir Ben-Tal²

Affiliations

¹ Tel Aviv University, George S. Wise Faculty of Life Sciences, Department of Biochemistry and Molecular Biology, Tel Aviv, Israel.
² Tel Aviv University, George S. Wise Faculty of Life Sciences, Department of Biochemistry and Molecular Biology, Tel Aviv, Israel. Electronic address: bental@tauex.tau.ac.il.

PMID: 36934025
DOI: 10.1016/j.tips.2023.02.006

Abstract

Cation/proton antiporters (CPAs) regulate cells' salt concentration and pH. Their malfunction is associated with a range of human pathologies, yet only a handful of CPA-targeting therapeutics are presently in clinical development. Here, we discuss how recently published mammalian protein structures and emerging computational technologies may help to bridge this gap.

Keywords: cation/proton antiporters; computational biology; pharmacology.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antiporters* / metabolism
Cations / metabolism
Humans
Hydrogen-Ion Concentration
Mammals / metabolism
Pharmaceutical Preparations
Protons*

Substances

Antiporters
Protons
Cations
Pharmaceutical Preparations